Phase 3 mixed dyslipidemia Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of AD-218
mixed dyslipidemia
Addpharma Inc.520 enrolled1 locationNCT05400317
Recruiting
Phase 3
Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia
Primary Hypercholesterolaemia and Mixed Dyslipidemia
Shanghai Junshi Bioscience Co., Ltd.582 enrolled1 locationNCT05621070
Not Yet Recruiting
Phase 3
A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145mg fenofibrate and simvastatin with 40mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone
Patients with mixed dyslipidemia with CHD or CHD risk equivalent or with multiple risk factor and a 10 year risk above or equal to 10% and with TG above 1.71mmol/l and LDL >2.58 or >3.36mmol/l according to risk after 6 weeks of treatment with 40mg simvastatin.
Fournier Laboratories Ireland400 enrolled1 locationACTRN12605000777695